Skip to main content

Table 1 Baseline characteristics

From: Quantiferon Gold-in-tube assay for TB screening in HIV infected children: influence of quantitative values

Characteristics QFT + (n = 15) QFT- (n = 65) P
Mean age 13.8(+/−3.5) 12.1+/−4.5 0.16
Age < 5 0 6(9%) 0.22
Females 5(33.3%) 38(57.5%) 0.09
Mean BMI 20.6+/−3.6 20.2+/−4.6 0.71
Born in TB endemic region 10(66.7%) 46(69.7%) 0.82
Mother born in TB endemic region 14(93.3%) 56(84.9%) 0.39
BCG vaccinated 6(40%) 20(30.3%) 0.47
Mean CD4% 31.4+/−11.3 32.1+/−9.3 0.79
CD4 > 25% 10(66.7%) 53(80.3%) 0.51
CD4 15-25% 4(26.7%) 10(15.2%)
CD4 < 15% 1(6.7%) 3(4.6%)
Mean CD4 count 744+/−331.5 846.7+/−483.8 0.44
Median CD4 count (IQR) 769(481–1043) 731(525–1012) 0.88
Viral load log10 copies/ml 3.6+/−1.3 3.5+/−0.86 0.87
Undetectable viral load 10(66.7%) 39(59.1%) 0.59
No symptoms* 5(33.3%) 18(27.3%) 0.91
Mild symptoms* 5(33.3%0 23(34.8%)
Moderate symptoms* 4(26.7%) 17(25.8%)
Severe symptoms* 1(6.7%) 8(12.1%)
Proportion on ARV 13(86.7%) 55(83.3%) 0.75
Median duration of ARV in years (IQR) 7.33(2.2-10.84) 8.04(1.84-11.8) 0.91
3TC monotherapy 0 4(6.1%) 0.73
Combination ART 13(86.7) 51(77.3%) 0.42
  1. *at initial presentation; BMI – Body Mass Index; CD 4 – Cluster of Differentiation 4; ARV – Anti Retroviral Therapy; 3TC –Lamivudine.